Log in to search using one of your social media accounts:


Surgeon David Mason Building Thoracic Program at Baylor in Dallas

A decade after thoracic surgeon and mesothelioma specialist Dr. David Mason built his practice at the Cleveland Clinic, he has begun building a new multidisciplinary program at Baylor University Medical Center in Dallas. The progression has been invigorating for Mason, the center's new chief of thoracic surgery and lung transplantation, as well as for the patients he now serves. Mason is constructing the new thoracic surgery program - the first of its kind in Dallas - that will attract top specialists in pulmonology, radiology, pathology, oncology and surgery. These specialists will work together to improve patient care across Texas. A major part of it will be a thoracic oncology department, which will include a new focus on pleural mesothelioma cancer. "It's almost like starting from scratch, bringing all the parts together," Mason told Asbestos.com. "It's exciting to build something like this from the ground floor, taking your experiences over time and putting them together to build the best possible program. I think patients will benefit greatly." Mason will be drawing from his years at the Cleveland Clinic, Johns Hopkins Hospital in Baltimore and Brigham and Women's Hospital in Boston. He is taking the best ideas from each, while leaving behind those that didn't work so well. "Sometimes, starting from scratch is easier than changing what someone else had previously done," he said. "It provides the opportunity to build a program the way y...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Authors: Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL Abstract Sarcomatoid mesothelioma (SM) is a devastating cancer associated with one of the poorest outcome. Therefore, representative preclinical models reproducing different tumor microenvironments (TME) observed in patients would open up new prospects for the identification of markers and evaluation of innovative therapies. Histological analyses of four original models of rat SM revealed their increasing infiltrative and metastatic potential were associated with differen...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Condition:   Mesothelioma, Malignant Interventions:   Drug: Nivolumab;   Drug: Ramucirumab Sponsors:   Arkadiusz Z. Dudek, MD;   HealthPartners Institute Regions Cancer Care Center;   Eli Lilly and Company;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Yale University alumni are pushing again to revoke the honorary degree given to Swiss billionaire Stephan Ernst Schmidheiny, whose asbestos-filled factories in Italy were responsible for the deaths of more than 2,000 people. Schmidheiny, 70, was sentenced to 16 years in prison and fined $15 billion in 2012 by an Italian court that found him negligent in protecting employees and nearby residents from deadly asbestos-related diseases such as mesothelioma. Schmidheiny received his honorary degree from Yale in 1996. In 2014, the university dismissed efforts by the Italy-based Asbestos Victims and Relatives Association and seve...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study investigates the clinical, histologic, immunohistochemical and molecular features of 10 MBAITs.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
DiscussionThe outcome of this trial will provide evidence of the potential benefit of the use of nivolumab in the treatment of relapsed mesothelioma. If found to be clinically effective, safe and cost-effective it is likely to become the new standard of care in the UK.Trial registrationEudraCT Number: 2016 –003111-35 (entered on 21 July 2016); ClinicalTrials.gov, ID:NCT03063450. Registered on 24 February 2017.
Source: Trials - Category: Research Source Type: clinical trials
Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ activating receptors on immune-effector cells. Amatuximab is a mAb targeting mesothelin whose mechanism of action utilizes in part antibody-dependent cellular cytotoxicity (ADCC). It is being tested for its therapeutic activity in patients with mesothelioma in combination with first line standard-of-care. To determine if CA125 has immunosuppressive effects on amatuximab ADCC and associated ...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
AbstractSplenosis is a benign condition that can occur after splenic trauma or after surgery involving the spleen. These splenic implants are most often seen within the abdominal and pelvic cavities. On imaging, splenosis can be confused with multiple additional entities including metastatic disease, peritoneal carcinomatosis, peritoneal mesothelioma, abdominal lymphoma, renal cancer, hepatic adenomas, or endometriosis depending on its distribution. In all patients with history of splenic surgery or trauma, splenosis should be on the differential diagnosis of soft tissue nodules in the abdomen and pelvis, especially in the...
Source: Abdominal Imaging - Category: Radiology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular & Thoracic Surgery | Education | Environmental Health | Eyes | Health | Health Management | Heart | Heart Transplant | Hospital Management | Hospitals | Lung Transplant | Mesothelioma | Pathology | Radiology | Toxicology | Transplants | Women